WIKIMEDIA, REVISORWEBAllergan, the Ireland-based pharmaceutical company that makes Botox, is set to acquire Vitae Pharmaceuticals, which is developing treatments for psoriasis and other autoimmune conditions, for around $639 million. “The acquisition of Vitae is a strategic investment for Allergan that adds strength and depth to our innovative medical dermatology franchise,” said Allergan CEO Brent Saunders in a statement released this week (September 14). “Vitae has pioneered the discovery and development of highly differentiated first-in-class compounds in atopic dermatitis, psoriasis and autoimmune diseases, areas of medicine where innovation is needed for patients.”
The deal is expected to close by the end of this year.
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
